CHRDL2

Across TCGA pan-cancer cohorts, CHRDL2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CHRDL2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CHRDL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CHRDL2 is over-expressed in tumor.

LUAD are the cancer types where CHRDL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHRDL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.367	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

CHRDL2–LUAD

Open the LUAD breakdown →